SCHEMBL24253042

SCHEMBL24253042

Cc1cc2cc(Br)ccc2c(Cl)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
POLB P06746 2/20 0.38
HTT P42858 1/20 0.36
NR4A2 P43354 1/20 0.36
ALDH1A1 P00352 3/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.35
CACNA1B Q00975 1/20 0.35
APBA1 Q02410 1/20 0.35
MAPK1 P28482 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
NCEH1 Q6PIU2 1/20 0.35
CYP2A6 P11509 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30467767 1.00 MAPT (0.39) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL28962504 0.80 HTT (0.38) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL27251840 0.80 MPO (0.42) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL6849732 0.80 HTT (0.38) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30301874 0.80 HTT (0.38) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL30800385 0.80 HTT (0.38) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL3834430 0.77 HTT (0.36) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL393406 0.77 HTT (0.43) MAPTRXFP1HTTNR4A2ALDH1A1
SCHEMBL12302447 0.77 NT5E (0.38) CYP1A2CYP2D6CYP2C9CYP2C19RXFP1
SCHEMBL2457932 0.76 RXFP1 (0.39) MAPTCYP1A2CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAPT 1152/4885CYP1A2 2977/4885CYP2D6 2146/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 MAPT 1152/4885CYP1A2 2977/4885CYP2D6 2146/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 MAPT 1152/4885CYP1A2 2977/4885CYP2D6 2146/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH MAPT 4803/4885CYP1A2 4150/4885CYP2D6 3026/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 MAPT 4737/4885CYP1A2 3838/4885CYP2D6 2040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.